This is the blog for CARG, the Coronary Artery Rehabilitation Group, based in Saskatoon, Saskatchewan, Canada. It will contain items of interest to CARG's own members and anybody else interested in the latest news about rehabilitation and heart-related matters. Canadian charitable number: 89675 0163 RR 0001 || e-mail: carg.ca@gmail.com || website: carg.ca || Blog disclaimer
Wednesday, November 4, 2009
FDA won't accept Merck's application for new drug (USA)
"U.S. regulators won't accept drugmaker Merck's application for a new combination cholesterol pill that includes rival Pfizer's Lipitor, the world's top-selling drug. Merck & Co. disclosed the rare move by the Food and Drug Administration in a regulatory filing on Monday. The company had said about 2 1/2 years ago that it planned to make and market a cholesterol pill combining Pfizer Inc.'s Lipitor with Zetia, a cholesterol pill Merck jointly sells with partner Schering-Plough Corp. In September, Merck applied to the FDA for approval of its combo pill. But Merck says the FDA refused to file the application and instead is requiring more data on the manufacturing and stability of the drug. The FDA hasn't responded to requests for comment." AP
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment